Andrew Henderson

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study

Andrew Henderson, David L. Paterson, Mark D. Chatfield et al. · Clinical Infectious Diseases · 2020 · 147 citations · Full text

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i>, <i>Morganella morganii</i>, <i>Providencia</i> spp, or <i>Serratia marcescens</i>: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

Adam G. Stewart, David L. Paterson, Barnaby Edward Young et al. · Open Forum Infectious Diseases · 2021 · 85 citations · Full text

Cryptococcosis—the impact of delay to diagnosis

Chaw Aye, Andrew Henderson, Huimin Yu et al. · Clinical Microbiology and Infection · 2016 · 63 citations

Cryptococcosis—the Impact, Diagnosis, Pathology +5